Although it seems likely that some of the newly discovered diabetes genes act in a pathway that is targeted by GLP1 receptor-agonists or DPP-4 inhibitors, more research into both the mechanisms of the medication and the function of the genes is needed. The gene discussed is GLP1R; the disease is diabetes mellitus.